[go: up one dir, main page]

MX2010004967A - Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. - Google Patents

Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.

Info

Publication number
MX2010004967A
MX2010004967A MX2010004967A MX2010004967A MX2010004967A MX 2010004967 A MX2010004967 A MX 2010004967A MX 2010004967 A MX2010004967 A MX 2010004967A MX 2010004967 A MX2010004967 A MX 2010004967A MX 2010004967 A MX2010004967 A MX 2010004967A
Authority
MX
Mexico
Prior art keywords
bone
cancer
treating
bone cancer
preventing
Prior art date
Application number
MX2010004967A
Other languages
English (en)
Inventor
Carl L Manthey
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2010004967A publication Critical patent/MX2010004967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos terapéuticos para tratar a un sujeto que tiene, y métodos profilácticos para evitar en un sujeto el riesgo de (o ser susceptible a) desarrollar, cáncer óseo y la pérdida ósea y dolor óseo relacionados con el cáncer óseo, dicho método comprende la administración de un compuesto de fórmula (I) o un solvato, hidrato, tautómero o sal farmacéuticamente aceptable del mismo.
MX2010004967A 2007-11-02 2008-10-29 Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. MX2010004967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98497807P 2007-11-02 2007-11-02
PCT/US2008/081501 WO2009058801A1 (en) 2007-11-02 2008-10-29 Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer

Publications (1)

Publication Number Publication Date
MX2010004967A true MX2010004967A (es) 2010-07-30

Family

ID=40221776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004967A MX2010004967A (es) 2007-11-02 2008-10-29 Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.

Country Status (8)

Country Link
US (1) US20100256148A1 (es)
EP (1) EP2222298A1 (es)
JP (1) JP2011502991A (es)
CN (1) CN101917994A (es)
AU (1) AU2008318854A1 (es)
CA (1) CA2704517A1 (es)
MX (1) MX2010004967A (es)
WO (1) WO2009058801A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083124A1 (en) * 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
EP3083601B1 (en) * 2013-12-20 2020-09-09 Esteve Pharmaceuticals, S.A. Piperidine derivatives having multimodal activity against pain
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
CN105503927B (zh) * 2016-01-11 2017-04-26 沧州普瑞东方科技有限公司 一种合成3,6‑二氢‑2h‑吡(噻)喃‑4‑硼酸酯的方法
US20190083495A1 (en) * 2016-04-04 2019-03-21 Massachusetts Institute Of Technology Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
WO2024075696A1 (ja) 2022-10-03 2024-04-11 公立大学法人横浜市立大学 二環性構造を有するイミダゾピリジン誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516947A (pt) * 2004-10-22 2008-09-23 Janssen Pharmaceutica Nv inibidores de quinase c-fms

Also Published As

Publication number Publication date
CN101917994A (zh) 2010-12-15
WO2009058801A1 (en) 2009-05-07
AU2008318854A1 (en) 2009-05-07
EP2222298A1 (en) 2010-09-01
CA2704517A1 (en) 2009-05-07
JP2011502991A (ja) 2011-01-27
US20100256148A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MX2009009786A (es) Inhibidores de la via de hedgehog.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
IL251185A0 (en) mek inhibitors and methods of using them
TW200738725A (en) Unsaturated mTOR inhibitors
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
TN2012000622A1 (en) Combinations of kinase inhibitors for the treatment of cancer
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
PH12016502355B1 (en) Pharmaceutical composition
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EA200870454A1 (ru) Способ ингибирования c-kit киназы
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
IN2012DN02816A (es)
MX2007003272A (es) Tratamiento de la osteoporosis inducida por medio de la falta de androgenos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal